With a market capitalization of approximately $197.94 million, Compugen is actively working on several clinical-stage programs, including COM701, which targets immune checkpoints discovered through computational methods. The company has a solid financial position with a cash runway expected to last into 2029, supported by a non-dilutive transaction in December 2025 providing $65 million upfront and a potential $25 million milestone payment from AstraZeneca royalties.
Cyborg Score Rationale
The company's AI/ML-powered computational discovery platform addresses a critical need in oncology drug development. However, revenue of $2.2 million in Q1 2026 declined 4.7% year-over-year, continuing anemic top-line performance, while clinical trial progress and non-dilutive funding provide visibility.
Top Insights
On June 11, 2026, Compugen announced plans to present its latest progress on the MAIA-ovarian trial at the European Oncology Congress
The company has initiated the MAIA-ovarian adaptive platform trial to test COM701 as a maintenance therapy, with active patient enrollment across the United States, Israel, and France
Compugen has a collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Opdivo in patients with advanced solid tumors
Michele Holcomb joined as an independent director in February 2026, bringing 30+ years in biotech, pharmaceuticals and healthcare services, with experience in strategy, business development, and partnerships
Named Competitors
Opdivo — PD-1 immune checkpoint inhibitor
Keytruda — PD-1 checkpoint inhibitor for oncology
Jemperli — PARD1 checkpoint inhibitor
Recent Developments
(June 2026) Presented MAIA-ovarian trial progress at European Oncology Congress
(May 2026) Q1 2026 revenue of $2.18M slightly beat analyst estimates despite EPS miss
(February 2026) Appointed Michele Holcomb as independent director with biotech and pharma leadership experience
(December 2025) Secured $65M upfront from AstraZeneca royalty monetization with additional $25M milestone payment potential
Open the full interactive Compugen Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.